David Cortez named associate director of basic science research at VICC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

David Cortez was named associate director for Basic Science Research at Vanderbilt-Ingram Cancer Center.

Cortez, the Richard Armstrong Professor of Biochemistry, joined Vanderbilt University in 2002. He is an expert in the field of DNA damage response and repair and made seminal discoveries about the mechanisms that maintain genome integrity.

Cortez is a member of the editorial boards for Cell Reports and Molecular and Cellular Biology. Cortez has been a co-leader of the Genome Maintenance Research Program since its inception in 2007 at VICC, and served as director of Graduate Studies in the Department of Biochemistry at Vanderbilt University for eight years.

Cortez replaces Scott Hiebert, professor of biochemistry and Hortense B. Ingram Professor of Cancer Research, who has served in the role since 2008. Hiebert is a member of the National Cancer Advisory Board.

Hiebert will continue in his role as associate director for shared resources and another interim leadership role to be announced soon. He will continue to focus on the molecular mechanisms of acute leukemia and the action of tumor suppressors in his own research program.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login